PMC:7212949 / 58901-59475 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T329","span":{"begin":61,"end":67},"obj":"Body_part"},{"id":"T330","span":{"begin":151,"end":154},"obj":"Body_part"},{"id":"T331","span":{"begin":191,"end":201},"obj":"Body_part"},{"id":"T332","span":{"begin":206,"end":214},"obj":"Body_part"},{"id":"T333","span":{"begin":284,"end":290},"obj":"Body_part"},{"id":"T334","span":{"begin":325,"end":336},"obj":"Body_part"},{"id":"T335","span":{"begin":361,"end":371},"obj":"Body_part"}],"attributes":[{"id":"A329","pred":"fma_id","subj":"T329","obj":"http://purl.org/sig/ont/fma/fma32558"},{"id":"A330","pred":"fma_id","subj":"T330","obj":"http://purl.org/sig/ont/fma/fma55675"},{"id":"A331","pred":"fma_id","subj":"T331","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A332","pred":"fma_id","subj":"T332","obj":"http://purl.org/sig/ont/fma/fma62851"},{"id":"A333","pred":"fma_id","subj":"T333","obj":"http://purl.org/sig/ont/fma/fma32558"},{"id":"A334","pred":"fma_id","subj":"T334","obj":"http://purl.org/sig/ont/fma/fma62860"},{"id":"A335","pred":"fma_id","subj":"T335","obj":"http://purl.org/sig/ont/fma/fma62863"}],"text":"• Acute CVA (5.7%), impaired consciousness (14.8%), skeletal muscle injury (19.3%) more likely in severe disease (P \u003c 0.05, P \u003c 0.001)\n• Patients with CNS symptoms more likely to have lower `lymphocyte and platelet counts and higher BUN (P \u003c 0.05, P \u003c 0.01, P \u003c 0.05)\n• Patients with muscle injury more likely to have higher neutrophils, CRP, D-dimer and lower lymphocyte count (P \u003c 0.05, P \u003c 0.001, P \u003c 0.05, P \u003c 0.01)\n• Neurologic symptoms may be due to direct viral pathogenicity via hematogenous or retrograde neuronal spread, immunosuppression, or coagulation disorders"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T484","span":{"begin":8,"end":11},"obj":"Disease"},{"id":"T486","span":{"begin":68,"end":74},"obj":"Disease"},{"id":"T487","span":{"begin":291,"end":297},"obj":"Disease"},{"id":"T488","span":{"begin":553,"end":574},"obj":"Disease"}],"attributes":[{"id":"A484","pred":"mondo_id","subj":"T484","obj":"http://purl.obolibrary.org/obo/MONDO_0005098"},{"id":"A485","pred":"mondo_id","subj":"T484","obj":"http://purl.obolibrary.org/obo/MONDO_0011057"},{"id":"A486","pred":"mondo_id","subj":"T486","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A487","pred":"mondo_id","subj":"T487","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A488","pred":"mondo_id","subj":"T488","obj":"http://purl.obolibrary.org/obo/MONDO_0001531"}],"text":"• Acute CVA (5.7%), impaired consciousness (14.8%), skeletal muscle injury (19.3%) more likely in severe disease (P \u003c 0.05, P \u003c 0.001)\n• Patients with CNS symptoms more likely to have lower `lymphocyte and platelet counts and higher BUN (P \u003c 0.05, P \u003c 0.01, P \u003c 0.05)\n• Patients with muscle injury more likely to have higher neutrophils, CRP, D-dimer and lower lymphocyte count (P \u003c 0.05, P \u003c 0.001, P \u003c 0.05, P \u003c 0.01)\n• Neurologic symptoms may be due to direct viral pathogenicity via hematogenous or retrograde neuronal spread, immunosuppression, or coagulation disorders"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T597","span":{"begin":284,"end":290},"obj":"http://purl.obolibrary.org/obo/UBERON_0001630"},{"id":"T592","span":{"begin":52,"end":67},"obj":"http://purl.obolibrary.org/obo/UBERON_0001134"},{"id":"T593","span":{"begin":52,"end":67},"obj":"http://purl.obolibrary.org/obo/UBERON_0014892"},{"id":"T594","span":{"begin":52,"end":67},"obj":"http://www.ebi.ac.uk/efo/EFO_0000888"},{"id":"T595","span":{"begin":151,"end":154},"obj":"http://www.ebi.ac.uk/efo/EFO_0000302"},{"id":"T596","span":{"begin":151,"end":154},"obj":"http://www.ebi.ac.uk/efo/EFO_0000908"},{"id":"T598","span":{"begin":284,"end":290},"obj":"http://purl.obolibrary.org/obo/UBERON_0005090"},{"id":"T599","span":{"begin":284,"end":290},"obj":"http://www.ebi.ac.uk/efo/EFO_0000801"},{"id":"T600","span":{"begin":284,"end":290},"obj":"http://www.ebi.ac.uk/efo/EFO_0001949"}],"text":"• Acute CVA (5.7%), impaired consciousness (14.8%), skeletal muscle injury (19.3%) more likely in severe disease (P \u003c 0.05, P \u003c 0.001)\n• Patients with CNS symptoms more likely to have lower `lymphocyte and platelet counts and higher BUN (P \u003c 0.05, P \u003c 0.01, P \u003c 0.05)\n• Patients with muscle injury more likely to have higher neutrophils, CRP, D-dimer and lower lymphocyte count (P \u003c 0.05, P \u003c 0.001, P \u003c 0.05, P \u003c 0.01)\n• Neurologic symptoms may be due to direct viral pathogenicity via hematogenous or retrograde neuronal spread, immunosuppression, or coagulation disorders"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T39600","span":{"begin":8,"end":11},"obj":"Chemical"}],"attributes":[{"id":"A49395","pred":"chebi_id","subj":"T39600","obj":"http://purl.obolibrary.org/obo/CHEBI_85264"}],"text":"• Acute CVA (5.7%), impaired consciousness (14.8%), skeletal muscle injury (19.3%) more likely in severe disease (P \u003c 0.05, P \u003c 0.001)\n• Patients with CNS symptoms more likely to have lower `lymphocyte and platelet counts and higher BUN (P \u003c 0.05, P \u003c 0.01, P \u003c 0.05)\n• Patients with muscle injury more likely to have higher neutrophils, CRP, D-dimer and lower lymphocyte count (P \u003c 0.05, P \u003c 0.001, P \u003c 0.05, P \u003c 0.01)\n• Neurologic symptoms may be due to direct viral pathogenicity via hematogenous or retrograde neuronal spread, immunosuppression, or coagulation disorders"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T72","span":{"begin":553,"end":564},"obj":"http://purl.obolibrary.org/obo/GO_0050817"}],"text":"• Acute CVA (5.7%), impaired consciousness (14.8%), skeletal muscle injury (19.3%) more likely in severe disease (P \u003c 0.05, P \u003c 0.001)\n• Patients with CNS symptoms more likely to have lower `lymphocyte and platelet counts and higher BUN (P \u003c 0.05, P \u003c 0.01, P \u003c 0.05)\n• Patients with muscle injury more likely to have higher neutrophils, CRP, D-dimer and lower lymphocyte count (P \u003c 0.05, P \u003c 0.001, P \u003c 0.05, P \u003c 0.01)\n• Neurologic symptoms may be due to direct viral pathogenicity via hematogenous or retrograde neuronal spread, immunosuppression, or coagulation disorders"}

{"project":"LitCovid-sentences","denotations":[{"id":"T613","span":{"begin":135,"end":267},"obj":"Sentence"},{"id":"T614","span":{"begin":268,"end":419},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"• Acute CVA (5.7%), impaired consciousness (14.8%), skeletal muscle injury (19.3%) more likely in severe disease (P \u003c 0.05, P \u003c 0.001)\n• Patients with CNS symptoms more likely to have lower `lymphocyte and platelet counts and higher BUN (P \u003c 0.05, P \u003c 0.01, P \u003c 0.05)\n• Patients with muscle injury more likely to have higher neutrophils, CRP, D-dimer and lower lymphocyte count (P \u003c 0.05, P \u003c 0.001, P \u003c 0.05, P \u003c 0.01)\n• Neurologic symptoms may be due to direct viral pathogenicity via hematogenous or retrograde neuronal spread, immunosuppression, or coagulation disorders"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T1425","span":{"begin":134,"end":142},"obj":"CL:0000233"},{"id":"T1426","span":{"begin":401,"end":409},"obj":"SP_10"},{"id":"T1427","span":{"begin":411,"end":419},"obj":"SP_9"},{"id":"T1428","span":{"begin":424,"end":432},"obj":"SP_7"},{"id":"T1429","span":{"begin":439,"end":444},"obj":"SP_10"}],"text":"• Acute CVA (5.7%), impaired consciousness (14.8%), skeletal muscle injury (19.3%) more likely in severe disease (P \u003c 0.05, P \u003c 0.001)\n• Patients with CNS symptoms more likely to have lower `lymphocyte and platelet counts and higher BUN (P \u003c 0.05, P \u003c 0.01, P \u003c 0.05)\n• Patients with muscle injury more likely to have higher neutrophils, CRP, D-dimer and lower lymphocyte count (P \u003c 0.05, P \u003c 0.001, P \u003c 0.05, P \u003c 0.01)\n• Neurologic symptoms may be due to direct viral pathogenicity via hematogenous or retrograde neuronal spread, immunosuppression, or coagulation disorders"}